What do systematic reviews say?

Raloxifene vs placebo

• Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 110 participants
  Very low

Raloxifene vs placebo

It is very uncertain whether raloxifene changes death compared with placebo (very low certainty).

• Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic… 2021 · Cochrane Headline outcomes only
  RR 1
  2 studies · 110 participants
  Very low

Raloxifene vs placebo

The review found no eligible studies for this question.

• Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Any anti‐osteoporotic drugs vs placebo

Any anti‐osteoporotic drugs showed no clear difference in clinical fracture compared with placebo (moderate certainty).

• Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic… 2021 · Cochrane Headline outcomes only
  RR 0.91 [0.79, 1.05]
  4 studies · 5827 participants
  Moderate

Any anti‐osteoporotic drugs vs placebo

• Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 6081 participants
  Very low

Any anti‐osteoporotic drugs vs placebo

• Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 9054 participants
  Very low

Any anti‐osteoporotic drugs vs placebo

• Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 3998 participants
  Very low

Any anti‐osteoporotic drugs vs placebo

The review found no eligible studies for this question.

• Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Any anti‐osteoporotic drugs vs placebo

Any anti‐osteoporotic drugs showed no clear difference in adverse events compared with placebo (moderate certainty).

• Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic… 2021 · Cochrane Headline outcomes only
  RR 0.99 [0.98, 1]
  5 studies · 9054 participants
  Moderate

Any anti‐osteoporotic drugs vs placebo

• Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 4973 participants
  Low

Any anti‐osteoporotic drugs vs placebo

The review found no eligible studies for this question.

• Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Thromboelastography (TEG) or thromboelastometry (ROTEM) vs any comparison

Thromboelastography (TEG) or thromboelastometry (ROTEM) may leads to lower mortality longest compared with any comparison (low certainty).

• Thromboelastography (TEG) or thromboelastometry (ROTEM) to monitor haemostatic treatment versus usual care in adults… 2016 · Cochrane Headline outcomes only
  RR 0.52 [0.28, 0.95]
  8 studies · 717 participants
  Low

Thromboelastography (TEG) or thromboelastometry (ROTEM) vs standard laboratory test (SLT)‐guided transfusion

Thromboelastography (TEG) or thromboelastometry (ROTEM) may leads to lower mortality compared with standard laboratory test (SLT)‐guided transfusion (low certainty).

• Thromboelastography (TEG) or thromboelastometry (ROTEM) to monitor haemostatic treatment versus usual care in adults… 2016 · Cochrane Headline outcomes only
  RR 0.36 [0.16, 0.84]
  4 studies · 272 participants
  Low

Thromboelastography (TEG) or thromboelastometry (ROTEM) vs standard laboratory test (SLT)‐guided transfusion

Thromboelastography (TEG) or thromboelastometry (ROTEM) showed no clear difference in proportion of patients receiving PRBCs compared with standard laboratory test (SLT)‐guided transfusion (low certainty).

• Thromboelastography (TEG) or thromboelastometry (ROTEM) to monitor haemostatic treatment versus usual care in adults… 2016 · Cochrane Headline outcomes only
  RR 0.91 [0.83, 1]
  3 studies · 244 participants
  Low

Thromboelastography (TEG) or thromboelastometry (ROTEM) vs standard laboratory test (SLT)‐guided transfusion

Thromboelastography (TEG) or thromboelastometry (ROTEM) showed no clear difference in proportion of patients receiving FFP compared with standard laboratory test (SLT)‐guided transfusion (low certainty).

• Thromboelastography (TEG) or thromboelastometry (ROTEM) to monitor haemostatic treatment versus usual care in adults… 2016 · Cochrane Headline outcomes only
  RR 0.83 [0.49, 1.4]
  4 studies · 346 participants
  Low

Thromboelastography (TEG) or thromboelastometry (ROTEM) vs standard laboratory test (SLT)‐guided transfusion

Thromboelastography (TEG) or thromboelastometry (ROTEM) showed no clear difference in proportion of patients receiving platelets compared with standard laboratory test (SLT)‐guided transfusion (low certainty).

• Thromboelastography (TEG) or thromboelastometry (ROTEM) to monitor haemostatic treatment versus usual care in adults… 2016 · Cochrane Headline outcomes only
  RR 0.87 [0.68, 1.11]
  3 studies · 244 participants
  Low

Thromboelastography (TEG) or thromboelastometry (ROTEM) vs standard laboratory test (SLT)‐guided transfusion

Thromboelastography (TEG) or thromboelastometry (ROTEM) showed no clear difference in rate of surgical reintervention compared with standard laboratory test (SLT)‐guided transfusion (low certainty).

• Thromboelastography (TEG) or thromboelastometry (ROTEM) to monitor haemostatic treatment versus usual care in adults… 2016 · Cochrane Headline outcomes only
  RR 0.82 [0.46, 1.46]
  3 studies · 248 participants
  Low

Thromboelastography (TEG) or thromboelastometry (ROTEM) vs any comparison

Thromboelastography (TEG) or thromboelastometry (ROTEM) may leads to lower proportion of patients receiving PRBCs compared with any comparison (low certainty).

• Thromboelastography (TEG) or thromboelastometry (ROTEM) to monitor haemostatic treatment versus usual care in adults… 2016 · Cochrane Headline outcomes only
  RR 0.86 [0.79, 0.94]
  10 studies · 832 participants
  Low

Thromboelastography (TEG) or thromboelastometry (ROTEM) vs any comparison

Thromboelastography (TEG) or thromboelastometry (ROTEM) may leads to lower proportion of patients receiving FFP compared with any comparison (low certainty).

• Thromboelastography (TEG) or thromboelastometry (ROTEM) to monitor haemostatic treatment versus usual care in adults… 2016 · Cochrane Headline outcomes only
  RR 0.57 [0.33, 0.96]
  8 studies · 761 participants
  Low

Thromboelastography (TEG) or thromboelastometry (ROTEM) vs any comparison

Thromboelastography (TEG) or thromboelastometry (ROTEM) may leads to lower proportion of patients receiving platelets compared with any comparison (low certainty).

• Thromboelastography (TEG) or thromboelastometry (ROTEM) to monitor haemostatic treatment versus usual care in adults… 2016 · Cochrane Headline outcomes only
  RR 0.73 [0.6, 0.88]
  10 studies · 832 participants
  Low